The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Investigation of the possible efficacy and safety of lansoprazole co-administration with neoadjuvant chemotherapy in tumor response in women with breast cancer who will be planned for surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Dexlansoprazole; Lansoprazole

Criteria

Inclusion Criteria:

• Females with age ≥ 18 years old.

• Newly diagnosed breast cancer patients.

• Planned neoadjuvant chemotherapy.

Exclusion Criteria:

• Pregnancy.

• Nursing mothers.

• Active or uncontrolled infection.

• Presence of another malignancies.

• Inadequate blood picture.

• Serum Creatinine more than 1.5 mg /dl.

• AST and ALT more than 2.5 upper limit.

• History of known hypersensitivity to lansoprazole.